CION Ameerpet
If both ovaries were removed to treat ovarian cancer, menopause did not arrive gradually — it arrived overnight. For most women, hormone therapy afterwards is an option rather than a ban, and for the commonest ovarian cancer there is randomised evidence behind that. The answer does shift with your exact tumour subtype, so this page starts there.
For most women, yes. High-grade serous carcinoma, which accounts for the majority of ovarian cancers, is not oestrogen-driven in the way many breast cancers are. The evidence on HRT after ovarian cancer, including one randomised trial and several large observational studies, has not shown that hormone therapy shortens survival or brings the disease back sooner.
That is not a blanket yes. A minority of ovarian tumours are hormone-sensitive. Low-grade serous carcinoma, endometrioid carcinoma and granulosa cell tumours behave differently, and for those, systemic oestrogen is usually avoided or used only after a specialist discussion. Your histopathology report already names which one you had. That single line decides most of this page for you.
The other half of the decision is what happens if you take nothing. Losing both ovaries at 34 or 41 is not the same event as menopause at 51. Oestrogen falls in a day rather than over years, and the consequences — bone loss, cardiovascular risk, broken sleep, low mood, poor concentration and painful sex — are measurable rather than theoretical. Declining hormone therapy carries its own costs. Read more on surgical menopause after ovary removal.
High-grade serous, mucinous and germ cell tumours are not usually treated as hormone-sensitive. Low-grade serous, endometrioid and granulosa cell tumours are. The subtype is on the first page of your histopathology report.
If the uterus was removed with the ovaries, oestrogen can be given on its own. If it is still there, a progestogen is added to protect the womb lining. A technical detail, not a judgement on whether you may have treatment.
Early surgical menopause left untreated has real long-term costs to bone and heart health. The comparison is hormone therapy against those costs, not against a harmless alternative.
The largest randomised trial to ask this question directly — the Adjuvant Hormone Therapy (AHT) trial reported by Eeles and colleagues — allocated women treated for epithelial ovarian cancer either to hormone replacement therapy after surgery and chemotherapy, or to none. Hormone therapy did not shorten survival. Overall survival in the hormone therapy group was, if anything, better, though the trial was small and closed early, so it is read as reassurance rather than as proof of benefit. A later Cochrane systematic review reached the same conclusion, with the same caution about the strength of the evidence. Source: Eeles RA et al., Journal of Clinical Oncology (2015); Cochrane Database of Systematic Reviews (2020); ESMO–ESGO consensus conference on ovarian cancer.
Read this with your histopathology report open. These are the usual starting positions in specialist practice, not rules — your own oncologist can move from them for good reasons, in either direction.
| Tumour type | Usual position on systemic hormone therapy | Why |
|---|---|---|
| High-grade serous carcinoma | Generally considered acceptable, including in younger women after both ovaries are removed. | Not oestrogen-driven. This is the group the randomised trial evidence covers best. |
| Low-grade serous carcinoma | Usually avoided; decided case by case with the treating oncologist. | Frequently oestrogen-receptor positive, and hormone-blocking treatment is itself sometimes used against it. |
| Endometrioid carcinoma | Usually avoided, or used only with a specialist's agreement. | Often hormone-receptor positive, and it behaves like the endometrial cancers it resembles. |
| Clear cell carcinoma | Case by case, and often acceptable, with the raised clotting risk kept in view. | Not typically hormone-driven, but clear cell disease carries a higher background risk of blood clots. |
| Mucinous carcinoma | Generally considered acceptable. | Not usually hormone-receptor driven. |
| Granulosa cell and other sex cord-stromal tumours | Usually avoided. | These tumours produce hormones themselves and are commonly oestrogen-receptor positive. |
| Germ cell tumours | Generally considered acceptable, and often directly relevant, since these women are usually young. | Not hormone-driven. Fertility-sparing surgery may also have left one working ovary. |
| Borderline ovarian tumours | Usually acceptable for serous borderline tumours; more caution where the tumour was hormone-receptor positive. | Borderline tumours are not invasive cancers and are treated as a separate question. |
*Positions summarised from specialist gynaecologic-oncology practice and consensus guidance. None of it replaces the decision your own oncologist makes with your pathology in front of them.
Two women with the same diagnosis can be given different advice, for reasons that have nothing to do with one doctor being more cautious than another. These are the factors that genuinely change it.
The younger you were, the stronger the case for hormone therapy. A woman whose ovaries are removed at 35 faces roughly fifteen extra years without oestrogen compared with a woman who reaches menopause naturally. Bone density falls fastest in the first few years after that drop, and cardiovascular risk climbs over the longer term.
For that reason, hormone therapy after early surgical menopause is usually planned to continue to around the average age of natural menopause and then reviewed. Up to that age it is replacing what your body would still have been making, rather than adding something extra on top.
If a hysterectomy was done at the same operation, oestrogen can be given on its own. If the uterus is still in place, a progestogen has to be added, because oestrogen given alone thickens the lining of the womb over time and raises the risk of cancer there.
Check this rather than assume it. Fertility-sparing surgery in a young woman may have preserved the uterus and even one ovary, which changes the regimen, the dose, and often the conversation about pregnancy as well.
This is the situation where the usual answer reverses. Systemic hormone therapy is generally not given to women who have had breast cancer, whatever their ovarian tumour type, because most breast cancers are hormone-receptor positive and the concern about feeding a recurrence is a real one.
Non-hormonal treatment for hot flushes and close attention to bone health take its place. Low-dose vaginal treatment for dryness is a separate question and is not automatically ruled out — it is decided with your breast oncologist rather than assumed either way.
Carrying a BRCA variant does not by itself close the door. Women who have their ovaries removed to reduce risk, and who have not had breast cancer, are generally offered hormone therapy up to the age of natural menopause. The evidence so far does not suggest that this undoes the risk reduction the surgery achieved.
After an ovarian cancer diagnosis, the subtype rules above still apply, with your breast risk weighed alongside them. If genetic testing has not been done, it is worth doing, and not only for you — it changes what your sisters and daughters can be offered. CION provides genetic counselling and BRCA and HRD testing in-house.
These are the symptoms women most often endure in silence, and they have the most straightforward answer. Genitourinary symptoms respond well to low-dose vaginal oestrogen, which works locally and reaches the bloodstream in far smaller amounts than tablets or patches do.
For most women after ovarian cancer this is a reasonable option, and it is often still considered even where systemic hormone therapy is not. Non-hormonal moisturisers and lubricants help too and are usually used alongside. More on managing menopause after ovarian cancer.
Hormone therapy is usually a survivorship conversation rather than a mid-treatment one. Most oncologists prefer to finish chemotherapy, see the response, and then decide, partly because menopausal symptoms settle unpredictably in the months after treatment ends.
If you are on maintenance therapy, this is decided alongside it rather than instead of it. Raise it at a follow-up appointment rather than waiting to be asked. Menopause is left off the agenda in a great many oncology reviews unless the patient puts it there.
None of these means the cancer is back, and most have ordinary explanations. Each is a reason to ring your oncology team rather than wait for the next scheduled visit.
Particularly if the uterus is still in place. It usually reflects the regimen rather than anything sinister, but it is always examined rather than assumed.
The symptoms that brought you here the first time deserve the same attention now. New, most days, over a few weeks is the pattern to report.
Oestrogen slightly raises the risk of blood clots, and cancer raises it too. Sudden breathlessness or chest pain needs emergency assessment the same day.
Worth a prompt examination for any woman on hormone therapy, and more so if you carry a BRCA variant or have a family history of breast cancer.
A reason to review the route and the dose, not to stop abruptly. Tell the team before changing anything yourself.
Hormone therapy that is not working is a reason to adjust the regimen, not to conclude nothing can be done. Most women need at least one adjustment.
Call your oncology team on 1800-202-8726 rather than stopping treatment on your own. Stopping suddenly usually brings the symptoms back within days and tells you nothing useful.
Bring your histopathology report and your operation note. Your tumour subtype, whether the uterus is still there, and your age at surgery decide most of this — and all three are already written down.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centreTravelling for treatment? We may have a centre right where you are.
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Trained at AIIMS, Tata Memorial and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them - together.
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationShare your name and number — we'll call you back within 30 minutes to schedule your consultation.
No referral needed and no cost for the first consultation. If hormone therapy is not right for your tumour type, we will say so plainly and go through what else works.
This takes one consultation and the paperwork you already have. It is not a coin toss, and it should not be left hanging for years because nobody raised it.
The exact words matter: high-grade serous, low-grade serous, endometrioid, clear cell, mucinous, granulosa cell, or a germ cell tumour. Oestrogen and progesterone receptor status is sometimes reported alongside. If you cannot find it, bring the report and we will read it with you.
One ovary or both, and whether the uterus went with them. That decides whether oestrogen is given alone or with a progestogen, and whether any hormone production remains. The operation note answers it in a line.
Age at surgery, bone density, family history of osteoporosis or heart disease, and how disruptive the symptoms actually are day to day. A woman of 36 with broken sleep and joint pain is in a different position from a woman of 58 with occasional flushes.
A previous breast cancer, a history of blood clots, active liver disease or unexplained vaginal bleeding all change the answer, as does an oestrogen-receptor positive ovarian tumour. This is the short list that turns a yes into a longer discussion.
Patches and gels are absorbed through the skin and bypass the liver, which carries a lower clot risk than tablets — relevant after cancer, since cancer itself raises that risk. Local vaginal treatment is added where dryness is the main complaint.
Symptoms, side effects and blood pressure at about three months, then at least yearly alongside your cancer follow-up. Most women continue to around the average age of natural menopause, then reduce and reassess with bone protection in mind.
Being told no is not the end of the conversation. These are the routes used when systemic oestrogen is off the table, and between them they cover most of what women actually complain of.
Several non-hormonal prescription options genuinely help, including low doses of certain antidepressant-class and anti-seizure-class medicines, and a newer non-hormonal class acting on the brain's temperature-control pathway. Cognitive behavioural therapy has good evidence for flushes and for the broken sleep around them, and is under-used.
Non-hormonal moisturisers used regularly, and lubricants used for sex, help a large proportion of women. Low-dose vaginal oestrogen is a separate question from systemic HRT and is often still open, including after breast cancer, when agreed with your oncologist. See managing menopause after ovarian cancer.
A baseline bone density scan after early surgical menopause, then calcium and vitamin D, weight-bearing and resistance exercise, and bone-protecting treatment from the bisphosphonate class where the scan warrants it. Loss is fastest in the first few years after the ovaries stop, which is exactly when this is worth doing.
Frequently dismissed and rarely trivial. Treat the night sweats first, because much of the mood and concentration change follows from broken sleep. Where low mood persists, it is treated in its own right — psycho-oncology support is part of survivorship care, not an admission of weakness.
Menopause is the part of ovarian cancer care that most often falls through the gap. Treatment finishes, scans get booked, and nobody asks about hot flushes, sleep or sex. Women then spend years assuming hormone therapy is forbidden, simply because no one ever said otherwise.
Your first consultation at CION is free and runs to about 45 minutes — long enough to go through the histopathology report line by line and give you an actual position rather than a vague caution. Where the case is genuinely unclear, it goes to the tumour board rather than resting on one doctor's opinion.
Follow-up and survivorship care, chemotherapy, maintenance therapy, genetic counselling and BRCA and HRD testing are delivered in-house at CION across 35+ centres in Telangana and Andhra Pradesh, so this conversation can happen near where you live. Ovarian cancer surgery, including debulking, is coordinated with specialist gynaecologic-oncology surgeons at partner centres and may be billed there — we would rather say that plainly than have you discover it at a billing counter.
Free, unhurried, and with your reports in front of us. Long enough to cover the questions that get skipped in a five-minute review.
Where hormone sensitivity is genuinely uncertain, medical oncology, pathology and imaging discuss the case together rather than one clinician deciding alone.
BRCA and HRD testing with counselling before and after, which also settles what your sisters and daughters should be offered.
Survivorship follow-up, chemotherapy and maintenance therapy near home across Telangana and Andhra Pradesh, instead of repeated trips to one city hospital.
If you are still deciding on treatment rather than living after it, start with ovarian cancer treatment in Hyderabad or the complete ovarian cancer guide.
For most women, yes. The commonest type, high-grade serous carcinoma, is not driven by oestrogen, and the trial and observational evidence has not shown that hormone therapy shortens survival or brings the disease back sooner. The main exceptions are the hormone-sensitive tumours: low-grade serous carcinoma, endometrioid carcinoma and granulosa cell tumours, where systemic oestrogen is usually avoided or used only after a specialist discussion. A previous breast cancer, a history of blood clots or active liver disease also change the answer. The decision rests on your histopathology report, what was removed at surgery, and how old you were at the time, so it is a conversation to have with your oncologist rather than a rule you can look up.
The evidence available does not show that. In the randomised Adjuvant Hormone Therapy trial, women treated for epithelial ovarian cancer who took hormone replacement did not survive for shorter periods than those who did not; overall survival was, if anything, better in the hormone therapy group. The trial was small and closed early, so it is treated as reassurance rather than as proof of benefit, and a later Cochrane review came to the same guarded conclusion. What can be said honestly is that there is no good evidence of harm for the commonest subtype, and that fear of recurrence has kept many women away from treatment that would have improved their bones, their sleep and their quality of life for years.
Nothing dramatic on day one, which is part of the problem. Over the following years, bone density falls faster than it would after a natural menopause, and the risk of osteoporosis and fractures rises. Cardiovascular risk climbs over the longer term. Hot flushes, broken sleep, low mood, poor concentration, joint aches, vaginal dryness and painful sex are common and often persist. Women who lose ovarian function well before the average age of natural menopause and take no replacement have measurably worse long-term bone and heart outcomes. If hormone therapy is not appropriate for your tumour type, bone protection, non-hormonal treatment for flushes and local treatment for dryness all still apply, and should be arranged rather than left.
Low-grade serous carcinoma and endometrioid carcinoma are frequently oestrogen-receptor positive, so systemic oestrogen is usually avoided in those, and hormone-blocking treatment is sometimes used against the tumour itself. Granulosa cell tumours and other sex cord-stromal tumours produce hormones and are commonly receptor positive, so they too are generally kept off systemic hormone therapy. High-grade serous, mucinous and germ cell tumours are not usually treated as hormone-sensitive. Borderline tumours are a separate category and are usually approached less restrictively. If your report notes oestrogen or progesterone receptor status, bring that to the appointment; it often settles the discussion faster than the subtype name alone.
Not in practice. Low-dose vaginal oestrogen works locally on the vaginal and urinary tissues, and only a very small amount reaches the bloodstream compared with tablets, patches or gels. That is why it is often considered even where systemic hormone therapy is not, including for many women who have had breast cancer, when the oncologist agrees. It treats dryness, discomfort during sex and some urinary symptoms, but it will not help hot flushes, night sweats or bone density. Non-hormonal vaginal moisturisers used regularly, along with lubricants for sex, help a good proportion of women and are usually tried alongside it.
It adds a second consideration rather than reversing the first. Carrying a BRCA1 or BRCA2 variant does not itself rule out hormone therapy; women who have their ovaries removed to reduce risk and who have not had breast cancer are generally offered it up to the age of natural menopause, and the evidence so far does not suggest this undoes the benefit of the surgery. After an ovarian cancer diagnosis, your tumour subtype still leads the decision, with your breast cancer risk weighed alongside it. If you have already had breast cancer, systemic hormone therapy is generally not used. Genetic counselling and BRCA and HRD testing are provided in-house at CION.
The first consultation is free and runs to about 45 minutes, which is long enough to read your histopathology report and operation note properly and give you a clear position. Survivorship follow-up, chemotherapy, maintenance therapy, genetic counselling and BRCA and HRD testing are delivered in-house at CION, across more than 35 centres in Telangana and Andhra Pradesh. Debulking and other gynaecologic-oncology surgery is coordinated with specialist partner centres and may be billed there, and we say so upfront rather than leaving it to be discovered later. Where hormone sensitivity is genuinely uncertain, the case is reviewed at a tumour board rather than decided by one doctor.